Factors behind the responsiveness or resistance to mTOR inhibitors in DLBCL in immunocompetent patients are largely obscure at present and unknown in AR-DLBCL [5, 13]. The gene discussed is MTOR; the disease is diffuse large B-cell lymphoma.